DATA FROM NOVEL, EXPLORATORY ANALYSIS OF INTERMITTENT VALTOCO® (DIAZEPAM NASAL SPRAY) CIV USE INDICATES MORE THAN TWO-FOLD INCREASE IN MEAN INTERVAL BETWEEN SEIZURE CLUSTERS
Neurelis presents two posters at the 2nd North American Epilepsy Congress (NAEC) highlighting new analysis of change in timing between seizure clusters across 12 months, and final effectiveness and safety data from the Phase 3, open-label, repeat-dose study of VALTOCO SAN DIEGO, CA — May 5, 2022— Neurelis, Inc., today announced findings from a novel, […]